Co-Authors
This is a "connection" page, showing publications co-authored by MARK SEUNGWOOK KIM and ROBERT COLEMAN.
Connection Strength
0.512
-
Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Med. 2024 Aug; 13(15):e70031.
Score: 0.243
-
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer. Mol Cancer Ther. 2020 11; 19(11):2396-2406.
Score: 0.186
-
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther. 2019 05; 18(5):969-979.
Score: 0.042
-
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.
Score: 0.021
-
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46.
Score: 0.020